Home › Free Stock Grades › RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Grade
RYTM · Healthcare
A+
Market Cap
$7.0B
P/E Ratio
—
Revenue Growth (YoY)
+45.8%
Net Margin
-103.6%
Return on Equity
—
Dividend Yield
None
About Rhythm Pharmaceuticals, Inc.'s fundamentals
Rhythm Pharmaceuticals is a biotechnology company with a market capitalization of $7.0 billion that is experiencing strong revenue growth of 45.8% year-over-year, indicating expanding commercial traction. However, the company is currently unprofitable, operating at a net margin of -103.6% and reporting a net loss in its latest annual statement, which is typical for earlier-stage biotech firms investing heavily in research and development. The company does not pay a dividend, with all resources directed toward business operations and growth initiatives.